Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,627 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06828614Enrolling by invitation
Barriers to exercise in breast cancer patients
This study looks at the challenges women with breast cancer face when trying to exercise before, during, and after chemotherapy. It aims to understand what gets in the way so that better support can be offered.
ValenciaAges 18–65 - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06831955RecruitingPhase 2
Lifestyle program to boost chemo before breast cancer surgery
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
AntwerpAges 18 years+ - NCT06831838Recruiting
Pain management program for breast cancer survivors with joint pain
This trial tests a cognitive behavioral therapy (CBT) based program to help relieve joint and muscle pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. It aims to improve your quality of life and reduce symptoms.
Jacksonville, FloridaAges 18 years+ - NCT06831474RecruitingPhase 1
Rivaroxaban in breast milk after childbirth
This study looks at how a blood thinner called rivaroxaban enters breast milk after delivery. It may help women who need this medication while breastfeeding.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06830382Recruiting
HER2-PET scan for metastatic breast cancer treatment
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
SolnaAges 18 years+ - NCT06833255Recruiting
Support Program for Black Women Breast Cancer Survivors
This program pairs Black women who have completed breast cancer treatment with support to help them transition into survivorship. It offers mentorship based on how recently you finished treatment, with priority for those who had limited support or who identify as African American.
Buffalo, New YorkAges 18 years+ - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT06817226Recruiting
Breast cancer decision tool study for Latinas
This study tests a decision-making tool for Latina breast cancer survivors or those at high risk. It aims to help you make informed choices about breast surgery and reconstruction options.
Chapel Hill, North CarolinaAges 18 years+ - NCT05658341Recruiting
Program of exercise, nutrition, and support for breast cancer survivors
This study tests a combined program of physical activity, nutrition guidance, and supportive resources to improve quality of life for breast cancer survivors. It may help you feel better physically and emotionally after completing (or nearly completing) treatment.
La Rochelle, Charentes-maritimesAges 18–72 - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06797531Recruiting
Ribociclib Real-World Study in Early Breast Cancer
This study observes people with early-stage hormone receptor positive, HER2-negative breast cancer who are taking ribociclib (Kisqali) with hormone therapy after surgery. It aims to see how well the treatment works and how safe it is in real life.
RiyadhAges 18–99 - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Aurora, ColoradoAges 18 years+ - NCT06802757RecruitingPhase 2
Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Jinan, ShandongAges 18–70 - NCT06793306Enrolling by invitation
Breast cancer study comparing younger and older patients
This trial looks at differences between younger and older breast cancer patients to better understand the disease. If you had breast cancer between the ages of 18 and 75 and were treated in a Chinese hospital from 2000 to 2024, you might be able to help.
BeijingAges 18–75 - NCT06795529Recruiting
Palliative care support for metastatic breast cancer
This study tests a palliative care program designed to improve quality of life for people with metastatic breast cancer. It may help you better manage symptoms and coordinate care with your oncology team.
Boston, MassachusettsAges 18 years+ - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06174363Recruiting
Pain Relief Study for Breast Cancer Surgery
This study tests a combination pain medicine (Maxigesic) to see how well it controls pain after breast cancer surgery. It may help you need fewer opioids after your operation.
SeoulAges 20–70 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06791161Enrolling by invitation
Adjuvant therapy study for BRCA1/2 positive breast cancer
This study tests if additional treatment after surgery helps prevent breast cancer from returning. It is for people with hormone receptor-positive, HER2-negative breast cancer who have a BRCA1 or BRCA2 gene mutation and a high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT06787339RecruitingPhase 2
Capecitabine for low-risk triple negative breast cancer
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT06781762Recruiting
Breast cancer hormone therapy and its effects on heart and brain
This study looks at how starting a common hormone therapy for breast cancer (aromatase inhibitors) affects your heart and brain health over the short term. It compares women starting this treatment to healthy women who are not on the therapy.
Toronto, OntarioAges Any age
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,627 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.